Cell & Gene Therapy World Conference (CGTWC ) 2026

I hold a bachelor's degree in Fine Organic Synthesis from MIREA Institute and a master's in Molecular and Cellular Technology. During my master's, I worked at a research institute, gaining experience in organic synthesis and automated solid-phase synthesizers. I also attended a summer school at Harbin University on metabolism. I currently work at KromBIO in the molecular genetics laboratory, where I have developed skills in cell culture, bioinformatics, and advanced lab instrumentation. In parallel, I am pursuing independent study in CAR-T cell therapy.

Carolyn Brokowski’s scholarly pioneering work in biomedical engineering and bioethics, focusing on emerging, novel nucleic-acid-editing technologies, is recognized and esteemed internationally. Her formal educational training and experience bring unique depth and breadth to her work. She studied biomedical science, philosophy, law, and engineering at graduate levels. Throughout the COVID-19 pandemic, she helped to facilitate and oversee human opioid and anti-COVID-pharmaceutical clinical research trials in every dimension of health care— ranging from pre-hospital settings to emergency departments to surgical intensive care units — at Yale New Haven Hospitals. For over a decade, Carolyn was an active voting member of Yale University’s Institutional Review Board. She is completing a PhD, funded by the Department of War (Defense), in biomedical engineering at the School of Mechanical, Aerospace, and Manufacturing Engineering at the University of Connecticut.

Attending Physician of Chinese Medicine, M.D. and Ph.D. in TCM Internal Medicine. Visiting scholar at Harvard Medical School and Beth Israel Deaconess Medical Center. Dedicated to the clinical and translational research on the integrated Chinese and Western medicine prevention and treatment of gastrointestinal tumors.Currently serves as a committee member of the Prescription-Drug-Effect Relationship Branch of the China Association of Chinese Medicine, the Cancer Rehabilitation Committee of the Chinese Society of Gerontology and Geriatrics (CSGOR), the Tumor Committee of the Jiangsu Association of Integrative Medicine, and the Integrative Diagnosis and Treatment Committee of the Jiangsu Gerontological Society.Editorial board member of journals including TMR Modern Herbal Medicine, Annals of Translational Medicine, and Life Research. Has presided over or participated in multiple research projects funded by the National Natural Science Foundation of China as well as provincial and ministerial-level agencies, and has published over 30 academic papers in peer-reviewed journals.

Dr. Fils Landry Mpelle, Biologist; PhD in Microbiology- Molecular Biology bio-Informatics and Immunology from Marien Ngouabi University Brazzaville Congo in 2020 and a Master’s degree in Applied immunology and molecular Biology from the Marien Ngouabi University Brazzaville Congo in 2014. Biologist at United Nations clinic of Brazzaville Congo. Associate Professor of Microbiology and molecular biology at the Faculty of Health Sciences Marien NGOUABI University Brazzaville Congo. Associate Professor of Microbiology and Immunology at the Faculty of Applied Sciences University of Denis SASSOU NGUESSO Brazzaville Congo.

EDUCATION • 8/2008 – 5/2013: Doctoral degree – Molecular Biology – University of Missouri, USA • 9/2001 – 9/2005: Bachelor’s degree – Biotechnology – Nong Lam University, Vietnam EMPLOYMENT HISTORY • Associate Professor, Pharmaceutical Sciences Department South University, School of Pharmacy, 7/2025 – Now • Assistant Professor, Pharmaceutical Sciences Department South University, School of Pharmacy, 8/2023 – 6/2025 • Assistant Professor, Biochemistry & Molecular Biology Oklahoma State University, 8/2016 – 5/2022 • Visiting Assistant Professor, Biology Denison University, 8/2015– 5/2016 • Science Education Postdoctoral Associate University of Missouri, 8/2013 – 5/2015

Feng Qu is a PhD candidate at Purdue University specializing in RNA delivery systems. His research focuses on developing modular peptide-based nanoparticles using elastin-like polypeptides (ELPs) to enhance RNA stability and delivery efficiency. With a strong background in non-viral gene delivery and lipid nanoparticle (LNP) formulation, he aims to address challenges related to targeted delivery and therapeutic applications. Prior to his PhD, Feng gained industry experience in business development and platform evaluation at CRO and venture capital firms. He is passionate about advancing RNA therapeutics through innovative nanocarrier design.

Biography TBA

Guobao Chen paints intimate snapshots of travel and love, documenting fleeting moments of connection in the midst of secular life.

Dr. Fei Pan received his B.E. in Aircraft Design and Engineering and his M.E. in Aeronautical and Astronautical Science and Technology from Xi'an Jiaotong University (XJTU), China, in 2013 and 2016, respectively, and a Diplôme d'Ingénieur (M.E.) from Ecole Centrale de Lille, France in 2016. He completed his Ph.D. in Biomedical Engineering at City University of Hong Kong, China in 2021. He then worked as a postdoctoral researcher at the Hong Kong Centre for Cerebro-cardiovascular Health Engineering (COCHE) from 2021 to 2024. Since 2024, he is an Assistant Professor with the School of Interdisciplinary Studies at Lingnan University, Hong Kong, China. His research interests include robotics, computer vision, artificial intelligence, and biotechnology.

Dr. Hongyun Tai, with a PhD in Polymer Chemistry from the University of Nottingham and an MBA from Bangor University in UK, is an experienced entrepreneur and academic with over 20 years of expertise in biomaterials, gene therapy, and biotechnological innovations. As the CEO and co-founder of Branca Bunús Ltd. Since 2019, a pioneering biotech company specializing in non-viral gene therapy for rare genetic diseases like Epidermolysis Bullosa (EB) and the development of high-performance gene transfection reagents, Dr. Tai has been at the forefront of advancing novel therapeutic solutions for gene therapy and drug delivery systems.

Dr. Ling Wu is a cancer immunologist and advisor for the International Society of Pharmaceutical Engineering (ISPE). He is currently the co-founder of ChemT Biotechnology, which is advancing cell and gene therapy (CGT) with artificial intelligence technology. With over a decade of expertise in cell and gene therapy (CGT) research and development, Dr. Wu previously led the CGT group at BeiGene, driving advancements in therapeutic innovation. He was the recipient of the Outstanding Research Fellow Award, and earned a PhD from the National University of Singapore, where he focused on groundbreaking CGT methodologies.

Mary Schaheen is a strategic life sciences investor and accomplished business executive. As president of Prevail Partners LLC, she has built a powerful network of over 3,000 C-level and senior executives across the global life sciences industry. Through a hands-on, partnership-driven approach, she has positioned Prevail Partners as a force multiplier and risk reducer for its portfolio companies, actively supporting funding strategies, asset monetization, and exit pathways. Under her leadership, Prevail Partners has participated in over $10 billion in exits and licensing transactions, and has been involved in multiple IPOs within the past year. Mary and her team specialize in identifying high-potential clinical-stage therapeutics, both US and non-US, and maintain a growing interest in implantable medical devices. With a strong foundation in strategic capital deployment and deep industry connectivity, Mary brings more than capital, she brings a track record of execution, long-term vision, and trusted relationships that drive value across the biotech ecosystem.